Peter Jenkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Jenkins has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Clare Salmon
2 shared publicationsRebecca Milliner
2 shared publications- Sylvie D. Freeman
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
2 shared publications Anita Ashton
1 shared publicationAnne Welsh
1 shared publicationCathy Mannion
1 shared publication
Latest Publications
- Open Access
- 2 November 2011
- Published by Elsevier in Annals of Oncology
- Vol. 23 (7) , 1766-1771
Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer
We have previously developed a predictive model that identifies patients at increased risk of febrile neutropaenia (FN) following chemotherapy, based on pretreatment haematological indices. This study was designed to validate our earlier findings in a separate cohort of patients undergoing more myelosuppressive chemotherapy supported by growth factors. We conducted a retrospective analysis of 263 patients who had been treated with adjuvant docetaxel, adriamycin and cyclophosphamide (TAC) chemotherapy for breast cancer. All patients received prophylactic pegfilgrastim and the majority also received prophylactic antibiotics. Thirty-one patients (12%) developed FN. Using our previous model, patients in the highest risk group (pretreatment absolute neutrophil count ≤3.1 × 109/l and absolute lymphocyte count ≤1.5 × 109/l) comprised 8% of the total population and had a 33% risk of developing FN. Compared with the rest of the cohort, this group had a 3.4-fold increased risk of developing FN (P = 0.001) and a 5.2-fold increased risk of cycle 1 FN (P < 0.001). A simple model based on pretreatment differential white blood cell count can be applied to pegfilgrastim-supported patients to identify those who are at higher risk of FN.
- 2 November 2011
- Published by Elsevier in Annals of Oncology
- Vol. 23 (7) , 1766-1771
Open AccessValidation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer
We have previously developed a predictive model that identifies patients at increased risk of febrile neutropaenia (FN) following chemotherapy, based on pretreatment haematological indices. This study was designed to validate our earlier findings in a separate cohort of patients undergoing more myelosuppressive chemotherapy supported by growth factors. We conducted a retrospective analysis of 263 patients who had been treated with adjuvant docetaxel, adriamycin and cyclophosphamide (TAC) chemotherapy for breast cancer. All patients received prophylactic pegfilgrastim and the majority also received prophylactic antibiotics. Thirty-one patients (12%) developed FN. Using our previous model, patients in the highest risk group (pretreatment absolute neutrophil count ≤3.1 × 109/l and absolute lymphocyte count ≤1.5 × 109/l) comprised 8% of the total population and had a 33% risk of developing FN. Compared with the rest of the cohort, this group had a 3.4-fold increased risk of developing FN (P = 0.001) and a 5.2-fold increased risk of cycle 1 FN (P < 0.001). A simple model based on pretreatment differential white blood cell count can be applied to pegfilgrastim-supported patients to identify those who are at higher risk of FN.
- 1 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (14) , 2143-2149
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma
- 1 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (14) , 2143-2149
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma
- 1 September 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (1) , 97-103
Computed Tomography Appearance of Early Radiation Injury to the Lung: Correlation With Clinical and Dosimetric Factors
- 1 September 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (1) , 97-103
Computed Tomography Appearance of Early Radiation Injury to the Lung: Correlation With Clinical and Dosimetric Factors
- 4 May 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 80 (4) , 1023-1029
An Improved Model for Predicting Radiation Pneumonitis Incorporating Clinical and Dosimetric Variables
- 4 May 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 80 (4) , 1023-1029
An Improved Model for Predicting Radiation Pneumonitis Incorporating Clinical and Dosimetric Variables
- 4 December 2009
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 16 (4) , 251-255
Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity
Purpose. Dose-rounding of chemotherapy is increasingly being used in oncology departments to improve the efficiency of outpatient clinics. There is, however, no published data on the effect of this strategy on drug toxicity. Methods. We have analysed acute chemotherapy side effects in a cohort of 662 consecutive patients receiving adjuvant FEC (5-fluorouracil, epirubicin, cyclophosphamide) for breast cancer. A dose-rounding algorithm was used to deliver drug doses that were within 5% of the standard dose based on body surface area. Results. Patients receiving a rounded dose of chemotherapy that was higher than that calculated from their body surface area were not at increased risk of acute haematological or non-haematological toxicity. Conclusions. Dose-rounding of adjuvant FEC within the range ±5% is not associated with any difference in acute chemotherapy side effects. Longer term follow-up is required to determine whether patients receiving rounded doses below that calculated from their body surface area are at increased risk of relapse.
- 4 December 2009
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 16 (4) , 251-255
Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity
Purpose. Dose-rounding of chemotherapy is increasingly being used in oncology departments to improve the efficiency of outpatient clinics. There is, however, no published data on the effect of this strategy on drug toxicity. Methods. We have analysed acute chemotherapy side effects in a cohort of 662 consecutive patients receiving adjuvant FEC (5-fluorouracil, epirubicin, cyclophosphamide) for breast cancer. A dose-rounding algorithm was used to deliver drug doses that were within 5% of the standard dose based on body surface area. Results. Patients receiving a rounded dose of chemotherapy that was higher than that calculated from their body surface area were not at increased risk of acute haematological or non-haematological toxicity. Conclusions. Dose-rounding of adjuvant FEC within the range ±5% is not associated with any difference in acute chemotherapy side effects. Longer term follow-up is required to determine whether patients receiving rounded doses below that calculated from their body surface area are at increased risk of relapse.
- 1 December 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (5) , 1379-1384
Defining the Clinical Target Volume for Bladder Cancer Radiotherapy Treatment Planning
- 1 December 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (5) , 1379-1384
Defining the Clinical Target Volume for Bladder Cancer Radiotherapy Treatment Planning
- 1 December 2009
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 93 (3) , 396-401
A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer
- 1 December 2009
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 93 (3) , 396-401
A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer
- 13 August 2008
- Published by Elsevier in Annals of Oncology
- Vol. 20 (1) , 34-40
Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer
Background: A predictive model that identifies patients at risk of excessive neutropenia following chemotherapy would be valuable in guiding the use of supportive therapies. Patients and methods: We conducted a retrospective analysis of 741 patients who had received adjuvant 5-fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy for breast cancer. The cause of every schedule alteration was identified. The ability of pretreatment haematological indices to predict for excessive myelosuppression was assessed. Results: Pretreatment absolute neutrophil count (ANC) and absolute lymphocyte count (ALC) were strongly associated with the risk of neutropenic events (NEs), febrile neutropenia (FN) or receiving suboptimal chemotherapy dose intensity (DI < 85%). The timing and pattern of NEs suggest that they reflect intrinsic chemosensitivity rather than cumulative toxicity and that FN results from chance infection rather than protracted myelosuppression. By combining quintiles on the basis of the rank order of ANC and ALC, we defined five groups of patients with variable risks of NE (18%–52%), DI 20% and would qualify for primary prophylaxis with granulocyte colony-stimulating factor support under current guidelines.
- 13 August 2008
- Published by Elsevier in Annals of Oncology
- Vol. 20 (1) , 34-40
Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer
Background: A predictive model that identifies patients at risk of excessive neutropenia following chemotherapy would be valuable in guiding the use of supportive therapies. Patients and methods: We conducted a retrospective analysis of 741 patients who had received adjuvant 5-fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy for breast cancer. The cause of every schedule alteration was identified. The ability of pretreatment haematological indices to predict for excessive myelosuppression was assessed. Results: Pretreatment absolute neutrophil count (ANC) and absolute lymphocyte count (ALC) were strongly associated with the risk of neutropenic events (NEs), febrile neutropenia (FN) or receiving suboptimal chemotherapy dose intensity (DI < 85%). The timing and pattern of NEs suggest that they reflect intrinsic chemosensitivity rather than cumulative toxicity and that FN results from chance infection rather than protracted myelosuppression. By combining quintiles on the basis of the rank order of ANC and ALC, we defined five groups of patients with variable risks of NE (18%–52%), DI 20% and would qualify for primary prophylaxis with granulocyte colony-stimulating factor support under current guidelines.
- 1 February 2007
- Published by Elsevier in European Journal of Cancer
- Vol. 43 (3) , 544-548
Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer
- 1 February 2007
- Published by Elsevier in European Journal of Cancer
- Vol. 43 (3) , 544-548
Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer